Caris Life Sciences (CAI) Competitors

$14.69 -2.07 (-12.35%)

Closing price 05/13/2026 04:00 PM Eastern

Extended Trading

$14.63 -0.06 (-0.38%)

As of 04:19 AM Eastern

CAI vs. GH, FMS, BTSG, HIMS, and CELC

Should you buy Caris Life Sciences stock or one of its competitors? MarketBeat compares Caris Life Sciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Caris Life Sciences include Guardant Health (GH), Fresenius Medical Care AG & Co. KGaA (FMS), BrightSpring Health Services (BTSG), Hims & Hers Health (HIMS), and Celcuity (CELC). These companies are all part of the "healthcare" industry.

How does Caris Life Sciences compare to Guardant Health?

Guardant Health (NASDAQ:GH) and Caris Life Sciences (NASDAQ:CAI) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, risk, valuation and earnings.

Caris Life Sciences has lower revenue, but higher earnings than Guardant Health. Guardant Health is trading at a lower price-to-earnings ratio than Caris Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Guardant Health	$982.02M	13.30	-$416.28M	-$3.39	N/A
Caris Life Sciences	$812.03M	5.11	-$68.09M	-$7.61	N/A

In the previous week, Caris Life Sciences had 2 more articles in the media than Guardant Health. MarketBeat recorded 27 mentions for Caris Life Sciences and 25 mentions for Guardant Health. Guardant Health's average media sentiment score of 0.56 beat Caris Life Sciences' score of 0.15 indicating that Guardant Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Guardant Health	7 Very Positive mention(s)	2 Positive mention(s)	11 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Caris Life Sciences	4 Very Positive mention(s)	3 Positive mention(s)	7 Neutral mention(s)	6 Negative mention(s)	1 Very Negative mention(s)	Neutral

92.6% of Guardant Health shares are owned by institutional investors. 5.6% of Guardant Health shares are owned by insiders. Comparatively, 7.8% of Caris Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Caris Life Sciences has a net margin of 3.75% compared to Guardant Health's net margin of -40.10%. Caris Life Sciences' return on equity of 98.28% beat Guardant Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Guardant Health	-40.10%	N/A	-26.42%
Caris Life Sciences	3.75%	98.28%	48.87%

Guardant Health currently has a consensus price target of $129.42, indicating a potential upside of 31.43%. Caris Life Sciences has a consensus price target of $27.56, indicating a potential upside of 87.58%. Given Caris Life Sciences' higher probable upside, analysts plainly believe Caris Life Sciences is more favorable than Guardant Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Guardant Health	1 Sell rating(s)	1 Hold rating(s)	19 Buy rating(s)	0 Strong Buy rating(s)	2.86
Caris Life Sciences	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Caris Life Sciences beats Guardant Health on 8 of the 15 factors compared between the two stocks.

How does Caris Life Sciences compare to Fresenius Medical Care AG & Co. KGaA?

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) and Caris Life Sciences (NASDAQ:CAI) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, risk and dividends.

Fresenius Medical Care AG & Co. KGaA has a net margin of 4.88% compared to Caris Life Sciences' net margin of 3.75%. Caris Life Sciences' return on equity of 98.28% beat Fresenius Medical Care AG & Co. KGaA's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fresenius Medical Care AG & Co. KGaA	4.88%	8.90%	4.05%
Caris Life Sciences	3.75%	98.28%	48.87%

Fresenius Medical Care AG & Co. KGaA presently has a consensus price target of $28.00, suggesting a potential upside of 30.99%. Caris Life Sciences has a consensus price target of $27.56, suggesting a potential upside of 87.58%. Given Caris Life Sciences' stronger consensus rating and higher probable upside, analysts plainly believe Caris Life Sciences is more favorable than Fresenius Medical Care AG & Co. KGaA.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fresenius Medical Care AG & Co. KGaA	4 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.56
Caris Life Sciences	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Caris Life Sciences had 21 more articles in the media than Fresenius Medical Care AG & Co. KGaA. MarketBeat recorded 27 mentions for Caris Life Sciences and 6 mentions for Fresenius Medical Care AG & Co. KGaA. Fresenius Medical Care AG & Co. KGaA's average media sentiment score of 1.19 beat Caris Life Sciences' score of 0.15 indicating that Fresenius Medical Care AG & Co. KGaA is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fresenius Medical Care AG & Co. KGaA	3 Very Positive mention(s)	3 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Caris Life Sciences	4 Very Positive mention(s)	3 Positive mention(s)	7 Neutral mention(s)	6 Negative mention(s)	1 Very Negative mention(s)	Neutral

8.4% of Fresenius Medical Care AG & Co. KGaA shares are held by institutional investors. 7.8% of Caris Life Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Fresenius Medical Care AG & Co. KGaA has higher revenue and earnings than Caris Life Sciences. Caris Life Sciences is trading at a lower price-to-earnings ratio than Fresenius Medical Care AG & Co. KGaA, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fresenius Medical Care AG & Co. KGaA	$19.36B	0.62	$1.11B	$1.90	11.25
Caris Life Sciences	$812.03M	5.11	-$68.09M	-$7.61	N/A

Summary

Caris Life Sciences beats Fresenius Medical Care AG & Co. KGaA on 8 of the 15 factors compared between the two stocks.

How does Caris Life Sciences compare to BrightSpring Health Services?

BrightSpring Health Services (NASDAQ:BTSG) and Caris Life Sciences (NASDAQ:CAI) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, risk and dividends.

Caris Life Sciences has a net margin of 3.75% compared to BrightSpring Health Services' net margin of 2.27%. Caris Life Sciences' return on equity of 98.28% beat BrightSpring Health Services' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BrightSpring Health Services	2.27%	14.63%	4.41%
Caris Life Sciences	3.75%	98.28%	48.87%

BrightSpring Health Services presently has a consensus price target of $56.29, suggesting a potential downside of 0.38%. Caris Life Sciences has a consensus price target of $27.56, suggesting a potential upside of 87.58%. Given Caris Life Sciences' higher probable upside, analysts plainly believe Caris Life Sciences is more favorable than BrightSpring Health Services.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BrightSpring Health Services	0 Sell rating(s)	0 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	3.12
Caris Life Sciences	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Caris Life Sciences had 20 more articles in the media than BrightSpring Health Services. MarketBeat recorded 27 mentions for Caris Life Sciences and 7 mentions for BrightSpring Health Services. BrightSpring Health Services' average media sentiment score of 0.99 beat Caris Life Sciences' score of 0.15 indicating that BrightSpring Health Services is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BrightSpring Health Services	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Caris Life Sciences	4 Very Positive mention(s)	3 Positive mention(s)	7 Neutral mention(s)	6 Negative mention(s)	1 Very Negative mention(s)	Neutral

BrightSpring Health Services has higher revenue and earnings than Caris Life Sciences. Caris Life Sciences is trading at a lower price-to-earnings ratio than BrightSpring Health Services, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BrightSpring Health Services	$12.91B	0.85	$190.67M	$1.41	40.07
Caris Life Sciences	$812.03M	5.11	-$68.09M	-$7.61	N/A

Summary

BrightSpring Health Services beats Caris Life Sciences on 8 of the 14 factors compared between the two stocks.

How does Caris Life Sciences compare to Hims & Hers Health?

Hims & Hers Health (NYSE:HIMS) and Caris Life Sciences (NASDAQ:CAI) are both mid-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, media sentiment, valuation, dividends and profitability.

63.5% of Hims & Hers Health shares are held by institutional investors. 11.8% of Hims & Hers Health shares are held by insiders. Comparatively, 7.8% of Caris Life Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Caris Life Sciences has a net margin of 3.75% compared to Hims & Hers Health's net margin of -0.56%. Caris Life Sciences' return on equity of 98.28% beat Hims & Hers Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hims & Hers Health	-0.56%	6.10%	1.52%
Caris Life Sciences	3.75%	98.28%	48.87%

In the previous week, Hims & Hers Health had 46 more articles in the media than Caris Life Sciences. MarketBeat recorded 73 mentions for Hims & Hers Health and 27 mentions for Caris Life Sciences. Caris Life Sciences' average media sentiment score of 0.15 beat Hims & Hers Health's score of 0.08 indicating that Caris Life Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hims & Hers Health	17 Very Positive mention(s)	11 Positive mention(s)	9 Neutral mention(s)	24 Negative mention(s)	4 Very Negative mention(s)	Neutral
Caris Life Sciences	4 Very Positive mention(s)	3 Positive mention(s)	7 Neutral mention(s)	6 Negative mention(s)	1 Very Negative mention(s)	Neutral

Hims & Hers Health presently has a consensus price target of $29.50, suggesting a potential upside of 22.37%. Caris Life Sciences has a consensus price target of $27.56, suggesting a potential upside of 87.58%. Given Caris Life Sciences' stronger consensus rating and higher possible upside, analysts clearly believe Caris Life Sciences is more favorable than Hims & Hers Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hims & Hers Health	2 Sell rating(s)	11 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.12
Caris Life Sciences	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50

Hims & Hers Health has higher revenue and earnings than Caris Life Sciences. Caris Life Sciences is trading at a lower price-to-earnings ratio than Hims & Hers Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hims & Hers Health	$2.35B	2.34	$128.37M	$0.51	47.27
Caris Life Sciences	$812.03M	5.11	-$68.09M	-$7.61	N/A

Summary

Caris Life Sciences beats Hims & Hers Health on 9 of the 15 factors compared between the two stocks.

How does Caris Life Sciences compare to Celcuity?

Celcuity (NASDAQ:CELC) and Caris Life Sciences (NASDAQ:CAI) are both mid-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, media sentiment, valuation, dividends and profitability.

63.3% of Celcuity shares are held by institutional investors. 13.3% of Celcuity shares are held by insiders. Comparatively, 7.8% of Caris Life Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Caris Life Sciences has a net margin of 3.75% compared to Celcuity's net margin of 0.00%. Caris Life Sciences' return on equity of 98.28% beat Celcuity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celcuity	N/A	-203.17%	-52.68%
Caris Life Sciences	3.75%	98.28%	48.87%

In the previous week, Caris Life Sciences had 21 more articles in the media than Celcuity. MarketBeat recorded 27 mentions for Caris Life Sciences and 6 mentions for Celcuity. Celcuity's average media sentiment score of 1.28 beat Caris Life Sciences' score of 0.15 indicating that Celcuity is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Celcuity	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Caris Life Sciences	4 Very Positive mention(s)	3 Positive mention(s)	7 Neutral mention(s)	6 Negative mention(s)	1 Very Negative mention(s)	Neutral

Celcuity presently has a consensus price target of $134.50, suggesting a potential upside of 8.06%. Caris Life Sciences has a consensus price target of $27.56, suggesting a potential upside of 87.58%. Given Caris Life Sciences' higher possible upside, analysts clearly believe Caris Life Sciences is more favorable than Celcuity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celcuity	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Caris Life Sciences	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50

Caris Life Sciences has higher revenue and earnings than Celcuity. Celcuity is trading at a lower price-to-earnings ratio than Caris Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celcuity	N/A	N/A	-$177.04M	-$3.79	N/A
Caris Life Sciences	$812.03M	5.11	-$68.09M	-$7.61	N/A

Summary

Caris Life Sciences beats Celcuity on 8 of the 14 factors compared between the two stocks.

Get Caris Life Sciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CAI vs. The Competition

Export

Metric	Caris Life Sciences	Services – Health Industry	Services Sector	NASDAQ Exchange
Market Cap	$4.74B	$1.55B	$1.02B	$12.20B
Dividend Yield	N/A	N/A	4.82%	5.30%
P/E Ratio	-1.93	13.83	10.28	25.58
Price / Sales	5.11	4.99	24.70	78.80
Price / Cash	10.51	3,156.44	426.65	55.34
Price / Book	7.00	40.37	6.40	6.66
Net Income	-$68.09M	-$26.94M	$64.39K	$333.63M
7 Day Performance	-25.96%	-5.78%	15.50%	-0.12%
1 Month Performance	-27.24%	-3.54%	39.55%	3.93%
1 Year Performance	N/A	N/A	25.43%	36.07%

Caris Life Sciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CAI Caris Life Sciences	4.3341 of 5 stars	$14.69 -12.4%	$27.56 +87.6%	N/A	$4.74B	$812.03M	N/A	1,846	Analyst Upgrade Insider Trade Gap Down High Trading Volume
GH Guardant Health	3.3739 of 5 stars	$95.70 +3.7%	$129.16 +35.0%	+138.1%	$12.69B	$982.02M	N/A	2,506	Analyst Forecast Insider Trade
FMS Fresenius Medical Care AG & Co. KGaA	4.8719 of 5 stars	$22.02 +1.7%	$28.00 +27.2%	-23.6%	$12.31B	$22.20B	11.59	1,488
BTSG BrightSpring Health Services	3.5368 of 5 stars	$54.83 +3.6%	$56.29 +2.7%	+143.1%	$10.63B	$12.91B	38.89	23,500
HIMS Hims & Hers Health	4.2443 of 5 stars	$28.46 +11.0%	$31.86 +11.9%	-62.3%	$6.44B	$2.35B	55.81	2,442	Trending News Earnings Report Analyst Forecast Options Volume Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CAI) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Caris Life Sciences (CAI) Competitors

CAI vs. GH, FMS, BTSG, HIMS, and CELC

How does Caris Life Sciences compare to Guardant Health?

Summary

How does Caris Life Sciences compare to Fresenius Medical Care AG & Co. KGaA?

Summary

How does Caris Life Sciences compare to BrightSpring Health Services?

Summary

How does Caris Life Sciences compare to Hims & Hers Health?

Summary

How does Caris Life Sciences compare to Celcuity?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CAI vs. The Competition

Caris Life Sciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Caris Life Sciences (CAI) Competitors

CAI vs. GH, FMS, BTSG, HIMS, and CELC

How does Caris Life Sciences compare to Guardant Health?

Which has stronger valuation and earnings, GH or CAI?

Does the media refer more to GH or CAI?

Do institutionals and insiders believe in GH or CAI?

Is GH or CAI more profitable?

Do analysts rate GH or CAI?

Summary

How does Caris Life Sciences compare to Fresenius Medical Care AG & Co. KGaA?

Is FMS or CAI more profitable?

Do analysts recommend FMS or CAI?

Does the media refer more to FMS or CAI?

Do insiders & institutionals hold more shares of FMS or CAI?

Which has preferable earnings and valuation, FMS or CAI?

Summary

How does Caris Life Sciences compare to BrightSpring Health Services?

Is BTSG or CAI more profitable?

Do analysts recommend BTSG or CAI?

Does the media refer more to BTSG or CAI?

Which has preferable earnings and valuation, BTSG or CAI?

Summary

How does Caris Life Sciences compare to Hims & Hers Health?

Do institutionals & insiders hold more shares of HIMS or CAI?

Is HIMS or CAI more profitable?

Does the media favor HIMS or CAI?

Do analysts recommend HIMS or CAI?

Which has better valuation & earnings, HIMS or CAI?

Summary

How does Caris Life Sciences compare to Celcuity?

Do institutionals & insiders hold more shares of CELC or CAI?

Is CELC or CAI more profitable?

Does the media favor CELC or CAI?

Do analysts recommend CELC or CAI?

Which has better valuation & earnings, CELC or CAI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CAI vs. The Competition

Caris Life Sciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools